Ontuxizumab

Ontuxizumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Morphotek.

History

Ontuxizumab was developed by Morphotek, a subsidiary of Eisai Co.. The drug is a monoclonal antibody that targets endosialin, a protein that is overexpressed in many types of cancer.

Mechanism of Action

Ontuxizumab works by targeting endosialin, a protein that is overexpressed in many types of cancer. By binding to this protein, ontuxizumab can inhibit the growth and spread of cancer cells.

Clinical Trials

Ontuxizumab has been tested in several clinical trials for its effectiveness in treating various types of cancer. These trials have shown promising results, but further research is needed to confirm these findings.

Side Effects

Like all drugs, ontuxizumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and decreased appetite. More serious side effects can also occur, but these are less common.

See Also

• Monoclonal antibodies
• Cancer treatment
• Morphotek
• Eisai Co.

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia